Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-Beyond: Denosumab in Early Breast Cancer
NCT01864798Phase 2Terminated
- Sponsor
- Institut Jules Bordet
- Start
- Jul 2013
- Primary completion
- Jan 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of denosumab in breast cancer, sponsored by Institut Jules Bordet. Started Jul 2013; status: terminated.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01864798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01864798.